Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Debt (2021)

Barinthus Biotherapeutics' Total Debt history spans 1 years, with the latest figure at $159000.0 for Q4 2021.

  • For Q4 2021, Total Debt changed N/A year-over-year to $159000.0; the TTM value through Dec 2021 reached $159000.0, changed N/A, while the annual FY2021 figure was $159000.0, N/A changed from the prior year.
  • Total Debt reached $159000.0 in Q4 2021 per BRNS's latest filing.
  • In the past five years, Total Debt ranged from a high of $159000.0 in Q4 2021 to a low of $159000.0 in Q4 2021.